Compare Synchrony Financial (SYF) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Viatris Inc — how do they compare? Synchrony Financial trades at $77.5 (market cap $25.58B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Synchrony Financial is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| SYF | VTRS | |
|---|---|---|
Market Cap | $25.58B | $19.09B |
Sector | Financials | Health |
52-Week High | $88.47 | $17.86 |
52-Week Low | $63.78 | $9.49 |
Dividend Yield | 1.73% | 2.89% |
Enterprise Value | — | $31.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 8.06 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings beats and a strategic partnership with OpenAI for AI-driven commerce highlight growth initiatives. Analyst consensus is bullish with a $87.33 price target and no sell ratings.
The outlook remains positive given valuation appeal, consistent earnings performance, and AI partnership potential. Key risks include consumer credit deterioration amid economic uncertainty and increased investing cash outflows. Institutional ownership trends and strong buyback activity support the bullish case, but credit quality monitoring is essential.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
